WEDNESDAY, Sept. 18, 2024 -- Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b...

Pancreatic ductal adenocarcinoma (PDAC) is a deadly type of pancreatic cancer. It’s aggressive, meaning it grows fast and spreads quickly....

THURSDAY, Sept. 19, 2024 -- For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by...

THURSDAY, Sept. 19, 2024 -- For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer...

FRIDAY, Sept. 20, 2024 -- Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk...

BASKING RIDGE, N.J. & RAHWAY, N.J., September 17, 2024 – The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with...

23 September 2024 -- High-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd) compared to...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia, a common condition related to...